Benzinga | Aug 26, 2020 08:10AM EDT

Akebia Therapeutics Announces Commercial Launch Of VAFSEO Oral Treatment For Anemia Due To Chronic Kidney Disease, In Japan

CAMBRIDGE, Mass., Aug. 26, 2020 /PRNewswire/ -- Akebia Therapeutics(r), Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that vadadustat, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), is now commercially available in Japan as a treatment for anemia due to chronic kidney disease (CKD) under the trade name VAFSEO(tm). VAFSEO has been included in the Japan National Health Insurance drug price listing and was granted regulatory approval as a treatment for anemia due to CKD in both dialysis-dependent and non-dialysis dependent adult patients by the Ministry of Health, Labour and Welfare in Japan in June 2020. The starting dose for VAFSEO is indicated at 300 mg with a maximum dose indicated at 600 mg.